Brise Pharmaceuticals and AbbVie confirmed a licensing agreement for two preclinical migraine programs, with potential payments up to $757 million tied to development, regulatory, and commercial milestones. The companies said no upfront payment was disclosed, and Brise will handle discovery while AbbVie takes responsibility for global development and commercialization. Brise’s disclosure highlighted BR005, an oral small molecule in Phase II/III for acute migraine, as part of its pipeline supporting the partnership. The deal structure signals continued big-company interest in acquiring early migraine assets with late-stage potential. For migraine investors, the announcement ties an emerging China-based discovery engine to a large-scale global development platform.